Pfizer is implementing a “cost realignment program” expected to save the pharmaceutical giant at least $3.5 billion as it prepares for revenue drops for its COVID-19 vaccine and Paxlovid, a prescription pill for treating COVID-19, according to its updated full-year guidance.
